Oncology and Hematology - Global Oncology Academy

Episodes 1-16 of 296

CME/CE Meeting
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 08, 2024
Singapore
1.50 credits Learn more
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
CME/CE Live Broadcast
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 18, 2024
12:00 PM - 01:30 PM ET
1.50 credits Learn more
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Clinician's Roundtable
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Project Oncology®
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah McManus, MD
- Andrew Armstrong, MD, MSc
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0.25 credits
- Joyce O'Shaughnessy, MD
0.25 credits
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Project Oncology®
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
- Daniel Kwon, MD
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Project Oncology®
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Maximizing Adherence and Persistence via Patient Engagement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
1.25 credits 10 episodes
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits

Prev
1
2
3
…
18
19
Next

1/6